Agenus, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US00847G7051
USD
3.07
0.03 (0.99%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Agenus, Inc.
AnaptysBio, Inc.
Janux Therapeutics, Inc.
Caribou Biosciences, Inc.
4D Molecular Therapeutics, Inc.
UroGen Pharma Ltd.
Avidity Biosciences, Inc.
Entrada Therapeutics, Inc.
Dyne Therapeutics, Inc.
AN2 Therapeutics, Inc.
HilleVax, Inc.

Why is Agenus, Inc. ?

1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
  • Poor long term growth as Operating profit has grown by an annual rate 12.76% of over the last 5 years
  • The company has a negative book value of Rs 271.11 crore
  • The company has reported losses and also has negative networth. This is not a good sign for the investors. Either company will have to raise fresh capital or report profits to sustain going forward
2
With a growth in Operating Profit of 72.42%, the company declared Outstanding results in Mar 26
  • The company has declared positive results for the last 3 consecutive quarters
  • OPERATING CASH FLOW(Y) Highest at USD -87.53 MM
  • RAW MATERIAL COST(Y) Fallen by -14.27% (YoY)
  • NET SALES(Q) At USD 33.74 MM has Grown at 18.17%
3
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of -36.40%, its profits have risen by 66.8%
4
High Institutional Holdings at 44.06%
  • These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
  • Their stake has increased by 2.79% over the previous quarter.
stock-recommendationReal-Time Research Report

Verdict Report

How much should you hold?

  1. Overall Portfolio exposure to Agenus, Inc. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Agenus, Inc. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Agenus, Inc.
-36.04%
-0.96
85.52%
S&P 500
22.24%
1.91
13.23%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
5.31%
EBIT Growth (5y)
12.76%
EBIT to Interest (avg)
-1.35
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.01
Sales to Capital Employed (avg)
-0.12
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
44.06%
ROCE (avg)
41.67%
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.48
EV to EBIT
-21.99
EV to EBITDA
-42.81
EV to Capital Employed
8.92
EV to Sales
3.96
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-40.57%
ROE (Latest)
Negative BV
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

28What is working for the Company
OPERATING CASH FLOW(Y)

Highest at USD -87.53 MM

RAW MATERIAL COST(Y)

Fallen by -14.27% (YoY

NET SALES(Q)

At USD 33.74 MM has Grown at 18.17%

OPERATING PROFIT(Q)

Highest at USD 15.64 MM

OPERATING PROFIT MARGIN(Q)

Highest at 46.35 %

PRE-TAX PROFIT(Q)

Highest at USD 40.56 MM

NET PROFIT(Q)

Highest at USD 40.58 MM

-2What is not working for the Company
CASH AND EQV(HY)

Lowest at USD 37.99 MM

DEBTORS TURNOVER RATIO(HY)

Lowest at 4.55 times

Here's what is working for Agenus, Inc.

Pre-Tax Profit
At USD 40.56 MM has Grown at 307.85%
over average net sales of the previous four periods of USD -19.51 MM
MOJO Watch
Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (USD MM)

Net Profit
At USD 40.58 MM has Grown at 316.84%
over average net sales of the previous four periods of USD -18.71 MM
MOJO Watch
Near term Net Profit trend is very positive

Net Profit (USD MM)

Operating Cash Flow
Highest at USD -87.53 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Net Sales
At USD 33.74 MM has Grown at 18.17%
over average net sales of the previous four periods of USD 28.55 MM
MOJO Watch
Near term sales trend is positive

Net Sales (USD MM)

Operating Profit
Highest at USD 15.64 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (USD MM)

Operating Profit Margin
Highest at 46.35 %
in the last five periods
MOJO Watch
Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit
Highest at USD 40.56 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit
Highest at USD 40.58 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is positive

Net Profit (USD MM)

Raw Material Cost
Fallen by -14.27% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Agenus, Inc.

Cash and Eqv
Lowest at USD 37.99 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debtors Turnover Ratio
Lowest at 4.55 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling Debtors has slowed

Debtors Turnover Ratio